A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Clinical Trial Grant
Awarded By
Inhibrx, Inc
Start Date
May 17, 2022
End Date
August 23, 2026
Awarded By
Inhibrx, Inc
Start Date
May 17, 2022
End Date
August 23, 2026